Business
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C
About this update from Newamsterdam Pharma Company N.v.
[{"type":"text","content":" – Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p","length":85,"tagName":"div"}]